Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v26-FR Version v24-FR
Language French French
Date Updated 2023-03-06 2023-02-14
Drug Identification Number 02100606 02100606
Brand name MULTI 12 INJECTION MULTI 12 INJECTION
Common or Proper name MULTI-12 MULTI-12
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients VITAMIN B12 FOLIC ACID BIOTIN VITAMIN E DEXPANTHENOL PYRIDOXINE HYDROCHLORIDE NICOTINAMIDE VITAMIN B2 VITAMIN B1 VITAMIN D VITAMIN A ASCORBIC ACID VITAMIN B12 FOLIC ACID BIOTIN VITAMIN E DEXPANTHENOL PYRIDOXINE HYDROCHLORIDE NICOTINAMIDE VITAMIN B2 VITAMIN B1 VITAMIN D VITAMIN A ASCORBIC ACID
Strength(s) 1MCG 80MCG 12MCG 2UNIT 3MG 0.8MG 8MG 0.72MG 0.6MG 40UNIT 660UNIT 20MG 1MCG 80MCG 12MCG 2UNIT 3MG 0.8MG 8MG 0.72MG 0.6MG 40UNIT 660UNIT 20MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 5ML 5ML
ATC code B05XC B05XC
ATC description I.V. SOLUTION ADDITIVES I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-12-12 2022-12-12
Estimated end date 2023-02-17 2023-02-17
Actual end date 2023-03-03
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Baxter item : 6410 Product is available on allocation based on 50% of historical volumes Baxter item : 6410 Product is available on allocation based on 50% of historical volumes
Health Canada comments